CGIX:NSD-Cancer Genetics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 4.64

Change

0.00 (0.00)%

Market Cap

USD 0.05B

Volume

0.27M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Cancer Genetics, Inc., through its subsidiary, vivoPharm, Pty Ltd., provides contract research services primarily focusing on studies to guide drug discovery and development programs in the oncology and immuno-oncology fields. The company's clinical offerings include a portfolio of proprietary tests, such as comparative genomic hybridization microarrays and next generation sequencing panels, gene expression tests, and DNA fluorescent in situ hybridization probes targeting hematological, and human papillomavirus-associated cancers, which include cervical, anal, head, and neck cancers. It serves the biotechnology and pharmaceutical customers in the United States, Europe, and Australia. Cancer Genetics, Inc. was founded in 1999 and is headquartered in Rutherford, New Jersey.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-17 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

+4.63 (+2.34%)

USD79.44B 132.60 106.34
REGN Regeneron Pharmaceuticals, Inc

+12.43 (+2.37%)

USD55.78B 14.90 11.77
BNTX BioNTech SE

+10.35 (+5.08%)

USD49.23B -99,999.99 35.63
VRTX Vertex Pharmaceuticals Incorpo..

+0.87 (+0.46%)

USD48.53B 17.87 12.86
ALXN Alexion Pharmaceuticals, Inc

-0.58 (-0.32%)

USD39.90B 58.60 42.42
BGNE BeiGene, Ltd

-4.17 (-1.25%)

USD31.22B N/A N/A
GMAB Genmab A/S

-1.04 (-2.33%)

USD29.17B 26.59 3.71
SGEN Seagen Inc

+2.06 (+1.36%)

USD27.46B 42.22 39.29
RPRX Royalty Pharma plc

+0.52 (+1.19%)

USD26.73B 22.60 15.75
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing CGIX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 67.51% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 67.51% N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 30.70% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.70% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain 128.57% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 128.57% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 471.83% 98% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 471.83% 98% A+ 99% A+
Risk Return Profile  
Volatility (Standard Deviation) 1,043.41% 2% F 2% F
Risk Adjusted Return 45.22% 71% C- 66% D
Market Capitalization 0.05B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 10.13 N/A N/A N/A N/A
Price / Cash Flow Ratio -9.92 N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -68.71% N/A N/A N/A N/A
Return on Invested Capital -129.46% N/A N/A N/A N/A
Return on Assets -14.90% N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.56 N/A N/A N/A N/A
Short Percent 6.91% N/A N/A N/A N/A
Beta 2.72 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.